A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 5, 2017

Study Completion Date

January 5, 2017

Conditions
Rett Syndrome
Interventions
DRUG

NNZ-2566

Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

DRUG

Placebo

Strawberry flavored solution and Water for Injection

Trial Locations (12)

19104

Children's Hospital of Philadelphia, Philadelphia

29646

Greenwood Genetic Center, Greenwood

35233

University of Alabama, Birmingham

37235

Vanderbilt University, Nashville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55101

Gillette Children's Specialty Healthcare, Saint Paul

60612

Rush University Medical Center, Chicago

77030

Baylor College of Medicine, Houston

80045

Children's Hosptial Colorado, Aurora

92093

University of California, San Diego, San Diego

94609

UCSF Benioff Children's Hospital Oakland, Oakland

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

rettsyndrome.org

UNKNOWN

lead

Neuren Pharmaceuticals Limited

INDUSTRY

NCT02715115 - A Safety Study of NNZ-2566 in Pediatric Rett Syndrome | Biotech Hunter | Biotech Hunter